Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2014-01-22 Regulatory Filings
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Grant of Options
Regulatory Filings Classification · 98% confidence The document is explicitly marked with an "RNS Number" and contains a date and company announcement regarding the "Grant of options" to employees and directors, detailing the number of shares, exercise price, and total options held. This type of mandatory disclosure to the stock exchange, which details insider transactions (options granted to directors/employees), strongly aligns with the definition of Director's Dealing (DIRS) or a general regulatory announcement. Since it specifically details transactions/holdings by directors/executives (even if options), Director's Dealing (DIRS) is a strong candidate. However, the presence of the RNS header and the nature of the announcement (granting options, which affects capital structure and insider holdings) makes it a standard regulatory filing. Given the specific focus on option grants to directors and employees, it is most closely related to insider transactions. If DIRS is strictly for *share* transactions, this might fall under a general regulatory filing (RNS) or potentially Capital/Financing (CAP) due to the issuance of options. Reviewing the definitions: DIRS is for 'personal share transactions by company directors and executives (insider trades)'. Granting options is a form of insider dealing/remuneration disclosure. Since it is a formal RNS announcement detailing director/employee option grants, and it doesn't fit perfectly into SHA (Share Issue) or DEF 14A (Remuneration Report), the most appropriate general regulatory category for this specific RNS disclosure is RNS, or DIRS if we interpret option grants as covered under insider dealings. Given the explicit RNS header and the short length (Rule 2 applies if it were just announcing a report, but this *is* the report/announcement), RNS is the safest general classification for an RNS-originated filing. However, since it details director holdings/transactions (options), DIRS is highly relevant. Let's check DIRS again: 'Report of personal share transactions by company directors and executives (insider trades)'. Option grants are a form of executive compensation/insider transaction. I will classify it as DIRS due to the specific content regarding director option holdings, which is a form of insider transaction disclosure, while acknowledging it is delivered via RNS.
2014-01-22 English
Issue of Equity
Share Issue/Capital Change Classification · 98% confidence The document is identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content explicitly announces the 'Issue of equity' (issuance of 9,801,829 new ordinary shares) and provides the resulting total issued share capital figure for DTR compliance. This action—the issuance of new shares—directly corresponds to the definition of 'Share Issue/Capital Change' (SHA). Although it is an RNS announcement, the core subject matter is a specific capital structure change, making SHA a more precise classification than the general RNS fallback.
2014-01-16 English
Fundraising and Equity Swap
Share Issue/Capital Change Classification · 99% confidence The document is an announcement dated December 27, 2013, identified by the RNS Number '3787W'. The content explicitly states that the company 'is pleased to announce that it has raised, in aggregate, £2,900,000... through the issue of 892,307,692 new ordinary shares'. This describes a fundraising activity involving the issuance of new shares and associated financing structures (Equity Swap). This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it involves share issuance (SHA), the primary focus and context is the capital raising event itself. It is not a general regulatory filing (RNS) because it fits a more specific category (CAP). The document length is short (3262 chars), but it is the primary announcement of the financing event, not just an announcement *about* a report, so RPA/RNS is less appropriate than CAP.
2013-12-27 English
New Australian Patent Grant
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated 05 December 2013. It announces a specific corporate event: 'New Australian Patent Grant for ValiRx's Cancer Screening Gene Biomarker'. This is a specific, material announcement made to the market via the Regulatory News Service (RNS). While it contains detailed information, its primary function is to disseminate a specific piece of news (a patent grant) rather than being a comprehensive periodic report (like 10-K or IR) or a transcript (CT). Since it is a formal regulatory announcement that doesn't fit perfectly into the other specific categories (like DIV, DIRS, or MANG), the most appropriate classification is the general regulatory announcement category, RNS.
2013-12-05 English
Update re Positive VAL201 & Biomarker Unit Studies
Regulatory Filings Classification · 99% confidence The document starts with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content provides an 'Update re Positive VAL201 & Biomarker Unit Studies,' detailing positive preliminary results from laboratory studies on a therapeutic compound (VAL201) and associated biomarker work. This is an announcement of scientific/clinical progress, not a full financial report (like 10-K or IR), a formal earnings release (ER), or a management discussion (MDA). Since it is a general, non-periodic, non-financial update disseminated through the RNS system that doesn't fit into more specific categories like DIRS, DIV, or CAP, the most appropriate classification is the general regulatory filing category.
2013-11-28 English
Placing to raise £1m
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number : 1029T' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content announces a 'Placing to raise £1m' through the issuance of new ordinary shares and details the resulting enlarged issued share capital. This activity—raising capital via issuing new shares—falls directly under the definition of Capital/Financing Update (CAP). While it is an RNS announcement, the specific nature of the announcement (a capital raise/share issue) makes CAP a more precise classification than the general fallback RNS, although it is closely related to SHA (Share Issue/Capital Change). Since the primary focus is the fundraising event itself, CAP is appropriate, but given the context of an RNS announcement detailing a share issuance, SHA is also highly relevant. However, 'Placing to raise £1m' strongly suggests a financing activity. Let's re-evaluate the definitions: CAP is 'Updates on company fundraising, financing activities, or capital structure changes.' SHA is 'Announcement regarding new share issues, stock splits, or other capital changes.' Since this is explicitly a fundraising placement, CAP is the best fit for the *purpose* of the transaction, although SHA describes the *mechanism*. Given the structure of the definitions, CAP covers the fundraising aspect most directly. However, the document explicitly details the number of new shares issued and the resulting total share capital, which aligns perfectly with SHA. I will choose SHA as it describes the concrete action taken (issuing new shares) which is the core of the announcement, even though it was for fundraising.
2013-11-15 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.